Glycopyrronium Bromide, Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous

• A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending
  2024-514248-95-00 Phase III 3 countries Chiesi Farmaceutici S.p.A.
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 Phase II 8 countries Chiesi Farmaceutici S.p.A.
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p… Ended
  2023-503333-22-00 Phase III 11 countries Chiesi Farmaceutici S.p.A.
• Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE Ended
  2022-501029-19-00 Phase IV 1 country Hospices Civils De Lyon
• A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153… Ended
  2023-510172-31-00 Phase III 5 countries Chiesi Farmaceutici S.p.A.

Showing 1–5 of 5 trials